- This topic has 0 replies, 1 voice, and was last updated 4 years ago by
.
-
Posts
-
Bladder Cancer Canada is looking for patients who fit these criteria to complete a 20-minute survey about their views on potential new treatments for metastatic bladder cancer.
It is critical to also survey a subgroup of patients who have specific experience with avelumab (Bavencio) as a first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.
You do not need to live in Canada to respond to this survey.
Participate in Survey
DEADLINE: Respond by Sept. 16, 2020Why is your participation important?
The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of avelumab to treat stage IV (locally advanced or metastatic urothelial carcinoma), in patients who have previously received platinum-based chemotherapy. Bladder Cancer Canada will be making a submission to ensure that patient voices are represented and considered during the review process.
START SURVEY: https://www.surveymonkey.com/r/avelumabforbladdercancer
View this information on the pCODR website here. https://cadth.ca/avelumab-bavencio-urothelial-carcinoma-details
Questions can be addressed to info@bladdercancercanada.org or by calling 1-866-674-8889.
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.
- You must be logged in to reply to this topic.
